Pfizer says incremental share repurchases ‘not high priority at this point’

Asked during the company’s Q4 earnings call if the company can do more share buybacks given the current stock price, Pfizer CFO David Denton replied according to a transcript: "I think as we look at capital allocation at this point in time, we actually see a lot of opportunities to invest back into our business, both from a research perspective and importantly, getting behind our launches to make sure that we’re doing all that we can to ensure that our growth trajectory in ’25 and ’30 and those goals and aspirations become reality. So I think our best and highest use of capital right now is investing in our business, both internally as well as from a BD [business development] perspective. I would say never say never to an incremental share repurchase, but that’s not high on the priority list at this point."